PPARGC1A and metabolic dysfunction-associated steatotic liver disease: Previous studies have shown that HD improved NAFLD by promoting fatty acid β-oxidation through activating SIRT1/PGC1α in HFD models in vitro and in vivo (Nie et al., 2024).